Sanofi assists in the development of new coronavirus vaccines, and is expected to screen candidate vaccines within 6 months

Author: Zhang Jingru announced on February 19 that Sanofi Pasteur, the global vaccine division of Sanofi, cooperated with BARDA to accelerate the development of new coronavirus vaccine by using advanced gene recombination technology platform Photo source: Sanofi Pasteur Sanofi has previous experience in developing SARS vaccine To this end, David Loew, global head of Sanofi vaccine, said that it is hoped that the candidate new coronavirus vaccine will be screened and tested in vitro within six months, and will be ready for clinical research within one and a half years It is understood that Sanofi will use gene recombination technology to accelerate vaccine development Gene recombination technology can produce precise gene matching for the proteins on the surface of virus DNA sequence coding will be combined into the baculovirus expression platform DNA, and used to rapidly produce a large number of coronavirus antigens, which will stimulate the human immune system to resist the virus Compared with the traditional vaccine development platform, gene recombination technology is conducive to rapid development of vaccines, and large-scale preparation of vaccines in a shorter time Based on baculovirus expression platform, Sanofi has developed a recombinant influenza vaccine product which has been approved for marketing Meanwhile, Glaxo Smith Kline PLC, another international vaccine giant, said earlier this month that it would provide adjuvant platform technology to CEPI through cooperation The first agreement has been reached between GlaxoSmithKline and the University of Queensland in Australia The technology is designed to enhance the body's immune response to provide a stronger and more durable protection system In addition to the two vaccine giants, foreign companies joining in the research and development of new crown vaccine include Johnson & Johnson in the United States, inovio, a vaccine company in the United States, Moderna, Pasteur Research Institute in France, and curevac AG, a German enterprise Among them, Johnson & Johnson said it would use the Ebola platform to develop a new coronavirus vaccine In contrast, there are 19 enterprises that have publicly announced the research and development of new coronavirus vaccine in China The research and development of new coronavirus vaccine in China involves many technical routes, including inactivated vaccine, mRNA vaccine, recombinant protein vaccine, virus vector vaccine, DNA vaccine and so on Reference: [1] sanofijoins forces with U.S Department of health and human services to advance anovel coronavirus vaccine [2] sanofibriggs SARS experience to hunt for coronavirus vaccine [3] can the new coronavirus survive for up to 9 days in vitro? Sanofi will screen out the vaccine candidates within six months [4] novel coronavirus vaccine [5] Sanofi has been developed by gene recombinant technology platform to develop a new crown vaccine with gene recombination technology platform The fastest test of Jeni turtle is 1 years later.